BRISBANE, Calif., Aug. 5, 2021 /PRNewswire/ -- Second Genome,
a biotechnology company that leverages its proprietary platform
sg-4-sight to discover and develop precision therapies and
biomarkers from public and proprietary microbiome data, today
announced they are entering a strategic collaboration with Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) to identify microbiome
biomarkers associated with clinical response for their lead program
in gastroenterology, etrasimod.
Under the terms of the agreement, Second Genome will utilize its
proprietary sg-4-sight discovery engine to identify microbiome
biomarkers associated with clinical benefit or adverse effects
observed within data from the CULTIVATE clinical trial. Arena's
CULTIVATE trial is a Phase 2/3 clinical trial evaluating the
efficacy and safety of etrasimod, a next-generation, once-daily,
oral, highly selective sphingosine 1-phosphate (S1P) receptor
modulator, in patients with moderately-to-severely active Crohn's
disease. This work will help inform patient stratification and
optimize potential treatments for patients in the future.
"The multi-disciplinary capabilities of our sg-4-sight platform
and our team's deep expertise enable Second Genome to collaborate
with partners as we continue to advance our own pipeline of
precision therapeutics and biomarkers," said Karim Dabbagh, Ph.D., President and Chief
Executive Officer of Second Genome. "Arena shares our commitment to
unlocking innovative ways to improve human health. We look forward
to working with Arena and applying our sg-4-sight platform to
discover microbiome signals in Crohn's disease patients."
"There is substantial evidence that gut microbiome is
intricately involved in therapy response in gastrointestinal
diseases," said Amit D. Munshi,
President and Chief Executive Officer of Arena Pharmaceuticals. "We
are pleased to collaborate with Second Genome to discover
microbiome biomarkers predictive of clinical response as we
continue to progress our CULTIVATE clinical trial."
About Second Genome
Second Genome is a biotechnology
company that leverages its proprietary tech platform sg-4-sight to
discover and develop transformational precision therapies and
biomarkers through clinical development and commercialization based
on novel microbial genetic insights. We built a proprietary
microbiome-based drug discovery and development platform with
specialized microbiome profiling assays, lab reagents and cloud
scale databases, machine-learning analytics, customized protein
engineering techniques, phage library screening, mass spec analysis
and CRISPR, that we couple with traditional drug development
approaches to progress the development of therapies and diagnostics
for wide-ranging diseases. Second Genome is advancing a deep drug
discovery and biomarker pipeline with precision therapeutics and
biomarker programs in inflammatory bowel disease (IBD) and cancer,
with the lead programs IBD and cancer expected to enter clinical
development in 2022. We also collaborate with industry, academic
and governmental partners to leverage our microbiome platform and
data science. We hold a strategic collaboration with Gilead
Sciences, Inc., utilizing our proprietary platform and
comprehensive data sets to identify novel biomarkers associated
with clinical response to Gilead's investigational medicines. For
more information, please visit www.secondgenome.com.
About Arena Pharmaceuticals
ARENA Pharmaceuticals is a
team with a singular purpose – deliver important medicines to
patients. In a rapidly changing global market, we work with a sense
of urgency every day to understand the needs of all our
stakeholders, identify bold, sometimes disruptive, ideas to get
medicines to patients, and relentlessly execute until it's
done.
We are developing a richly diversified portfolio of therapeutic
candidates targeting gastroenterology, dermatology and cardiology.
Our pipeline includes four investigational medicines in eight
indications and eleven ongoing or planned clinical trials. To fuel
our growth, we are unlocking the value of our historical GPCR
research with a sustainable discovery engine for broad portfolio
expansion.
ARENA - Care More. Act Differently.
Investor Contact:
Argot Partners
212-600-1902
secondgenome@argotpartners.com
Media Contact:
Argot Partners
212-600-1902
secondgenome@argotpartners.com
View original
content:https://www.prnewswire.com/news-releases/second-genome-announces-collaboration-with-arena-pharmaceuticals-to-identify-gastrointestinal-biomarkers-301348964.html
SOURCE Second Genome